Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Bayer, Wilmer Eye Institute sign five-year deal

Executive Summary

Through a collaboration with Johns Hopkins University's Wilmer Eye Institute, Bayer HealthCare Pharmaceuticals AG received an option to license exclusive rights to drug candidates they discover and develop for multiple retinal diseases including AMD, diabetic macular edema, geographic atrophy, Stargardt's disease, and retinal vein occlusion.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register